The pathogenesis of dengue virus (DENV) is a complex interaction of both host immune responses and viral factors. One of the main mediators of this process is the non-structural protein (NS1) antigen that is released in early infection and has a direct causal effect on endothelial damage and an enhanced immune response. The structural similarity of NS1 with host proteins (e.g. glycocalyx constituents, endothelial cell-surface proteins, and coagulation factors) creates cross-reactive antibodies and attacks host tissues. This molecular mimicry leads to endothelial dysfunction, vascular permeability etc., which are characteristic of severe manifestations of Dengue such as dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Moreover, these cross-reactive antibodies have the capacity of binding to the antigens on the surface of the platelets that subsequently undergo Fc-mediated phagocytosis by the macrophages and cause thrombocytopenia. Homology between NS1 and coagulation factors can also interact with clotting cascades, which can lead to haemorrhagic tendencies among the infected cases. Antibody-dependent enhancement (ADE) facilitates DENV infection into Fc receptor, which carries immune cells, which increases viral replication and cytokine storms that enhance tissue destruction and vascular leakage in secondary infections. NS1 act as a key immunopathological mediator between the imbalances that are related to coagulation, vascular occlusion, and altered immune reaction to DENV infection. Knowledge of these NS1 mediated mechanisms helps in the implementation of targeted interventions to control severe clinical outcomes which will improve current treatment modalities as well as understanding of the strategy of vaccination.
Imran et al. (Thu,) studied this question.